ACADIA PHARMACEUTICALS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ACADIA PHARMACEUTICALS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $231.04M | Feb 28, 2024 |
| FY2023 | Sep 30, 2023 | $211.70M | Feb 28, 2024 |
| FY2023 | Jun 30, 2023 | $165.24M | Feb 28, 2024 |
| FY2023 | Mar 31, 2023 | $118.46M | Feb 28, 2024 |
| FY2023 | Dec 31, 2022 | $136.49M | Feb 28, 2024 |
| FY2023 | Sep 30, 2022 | $130.71M | Feb 28, 2024 |
| FY2023 | Jun 30, 2022 | $134.56M | Feb 28, 2024 |
| FY2023 | Mar 31, 2022 | $115.47M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $130.76M | Feb 28, 2023 |
| FY2022 | Sep 30, 2021 | $131.61M | Feb 28, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.07B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $957.80M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $726.44M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $517.24M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $484.15M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $441.76M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $339.08M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $223.81M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $124.90M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $17.33M | Feb 27, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $213.15M | Feb 28, 2024 |
| FY2023 | Sep 30, 2023 | $197.08M | Feb 28, 2024 |
| FY2023 | Jun 30, 2023 | $157.78M | Feb 28, 2024 |
| FY2023 | Mar 31, 2023 | $116.80M | Feb 28, 2024 |
| FY2023 | Dec 31, 2022 | $134.08M | Feb 28, 2024 |
| FY2023 | Sep 30, 2022 | $128.58M | Feb 28, 2024 |
| FY2023 | Jun 30, 2022 | $131.90M | Feb 28, 2024 |
| FY2023 | Mar 31, 2022 | $112.52M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $128.31M | Feb 28, 2023 |
| FY2022 | Sep 30, 2021 | $127.92M | Feb 28, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $391.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $226.45M | Feb 26, 2026 |
| FY2023 | Dec 31, 2023 | $45.80M | Feb 28, 2024 |
| FY2023 | Sep 30, 2023 | ($65.18M) | Feb 28, 2024 |
| FY2023 | Jun 30, 2023 | $1.11M | Feb 28, 2024 |
| FY2023 | Mar 31, 2023 | ($43.02M) | Feb 28, 2024 |
| FY2023 | Dec 31, 2022 | ($41.73M) | Feb 28, 2024 |
| FY2023 | Sep 30, 2022 | ($27.18M) | Feb 28, 2024 |
| FY2023 | Jun 30, 2022 | ($34.01M) | Feb 28, 2024 |
| FY2023 | Mar 31, 2022 | ($113.06M) | Feb 28, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $104.81M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $230.79M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($73.38M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($223.60M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($170.44M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($286.59M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($246.55M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($247.44M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($292.41M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($272.82M) | Feb 27, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $328.80M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $303.25M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $351.62M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $361.58M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $239.42M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $319.13M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $240.39M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $187.16M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $149.19M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $99.28M | Feb 27, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $548.89M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $488.43M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $406.56M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $369.09M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $396.03M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $388.66M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $325.64M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $265.76M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $255.06M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $186.46M | Feb 27, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.84M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $157.72M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $16.70M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($114.04M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($125.66M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($136.17M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($151.13M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($167.47M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($217.76M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($208.41M) | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.69M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $523.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $50.0K | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $1.12M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $7.59M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $1.13M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $2.10M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $812.0K | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $1.51M | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.56B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.19B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $748.96M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $587.81M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $700.12M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $782.62M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $783.18M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $540.20M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $384.51M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $561.15M | Feb 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $336.81M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $454.96M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $317.20M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $187.40M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $159.23M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $155.61M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $84.05M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $61.12M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $49.22M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $42.74M | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.23B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $732.79M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $431.76M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $400.41M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $540.89M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $627.01M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $699.14M | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | $479.08M | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | $335.29M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $518.41M | Feb 27, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.81B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($2.20B) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($2.43B) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($2.37B) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($2.15B) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($1.99B) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($1.70B) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($1.47B) | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($1.22B) | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | ($933.98M) | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $177.70M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $319.59M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $188.66M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $114.85M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $147.44M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $326.03M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $189.68M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $134.76M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $69.42M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $163.62M | Feb 27, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 26, 2026 |
| FY2023 | Dec 31, 2023 | 0 | Feb 28, 2024 |
| FY2023 | Sep 30, 2023 | 0 | Feb 28, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Feb 28, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Feb 28, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Feb 28, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Feb 28, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Feb 28, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Feb 28, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 26, 2026 |
| FY2023 | Dec 31, 2023 | 0 | Feb 28, 2024 |
| FY2023 | Sep 30, 2023 | 0 | Feb 28, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Feb 28, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Feb 28, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Feb 28, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Feb 28, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Feb 28, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Feb 28, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 170.31M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 166.71M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 164.65M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 162.06M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 161.01M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 159.64M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 155.28M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 143.85M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 124.41M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 121.37M | Feb 27, 2018 |